Drugs / SB-007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06942572 | Feb 2025 → Oct 2028 expected | Stargardt disease | Splice Bio | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06942572 ↗ |
| Action | Restore | “for the full-length reconstitution of the ABCA4 protein inside the target cell” NCT06942572 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “dual AAV8 gene delivery” NCT06942572 ↗ |
| Route | Other | “Subretinal Administration of SB-007” NCT06942572 ↗ |
| Target | ABCA4 | “reconstitution of the full-length biologically active ABCA4 protein in target photoreceptor cells” NCT06942572 ↗ |